ResearcherYonsei UniversityNo recent work listed
Dawoon Jung
Matched on ORCID iD 0000-0003-3612-7196; OpenAlex author ID A5101920480. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper
Papers 6
- Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective stud… Co-author DOI 10.3389/fonc.2023.1206565↗
- A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. First author DOI 10.1002/ijc.34144↗
- GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08898-y↗
- Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Co-author DOI 10.1038/s41598-018-21823-x↗
- The DNA aptamer binds stemness-enriched cancer cells in pancreatic cancer. Co-author DOI 10.1002/jmr.2591↗
- Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF-β pathway. Co-author DOI 10.1002/mc.22309↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Si Young Song · 6 shared papers, 2016–2023 · strength 0.68
- Paper Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients wi… DOI 10.3389/fonc.2023.1206565↗
- Paper A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced … DOI 10.1002/ijc.34144↗
- Paper GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-021-08898-y↗
- Hee Seung Lee · 5 shared papers, 2017–2023 · strength 0.60
- Paper Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients wi… DOI 10.3389/fonc.2023.1206565↗
- Paper A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced … DOI 10.1002/ijc.34144↗
- Paper GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-021-08898-y↗
- Moon Jae Chung · 4 shared papers, 2018–2023 · strength 0.51
- Paper Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients wi… DOI 10.3389/fonc.2023.1206565↗
- Paper A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced … DOI 10.1002/ijc.34144↗
- Paper GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-021-08898-y↗
- Jung Hyun Jo · 3 shared papers, 2021–2023 · strength 0.44
- Paper Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients wi… DOI 10.3389/fonc.2023.1206565↗
- Paper A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced … DOI 10.1002/ijc.34144↗
- Paper GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-021-08898-y↗
- Seung Woo Park · 3 shared papers, 2018–2023 · strength 0.38
- Paper Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients wi… DOI 10.3389/fonc.2023.1206565↗
- Paper A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced … DOI 10.1002/ijc.34144↗
- Paper Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. DOI 10.1038/s41598-018-21823-x↗
- Jeong Youp Park · 3 shared papers, 2018–2023 · strength 0.38
- Paper Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients wi… DOI 10.3389/fonc.2023.1206565↗
- Paper A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced … DOI 10.1002/ijc.34144↗
- Paper Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. DOI 10.1038/s41598-018-21823-x↗
- Seungmin Bang · 3 shared papers, 2018–2023 · strength 0.38
- Paper Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients wi… DOI 10.3389/fonc.2023.1206565↗
- Paper A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced … DOI 10.1002/ijc.34144↗
- Paper Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. DOI 10.1038/s41598-018-21823-x↗
- Chan Su Park · 1 shared paper, 2023 · strength 0.16
- Yoon‐Jin Kim · 1 shared paper, 2017 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.